New and recently funded Medical Startups
1
Country: Serbia
DeepDoctor MedTech Company's flagship product is DeepDoctor PRO, an AI-based physician's assistant that supports rapid generation of differential diagnoses in a structured clinical format.
DeepDoctor MedTech Company's flagship product is DeepDoctor PRO, an AI-based physician's assistant that supports rapid generation of differential diagnoses in a structured clinical format.
2
Country: Switzerland | Funding: $200M
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
Windward Bio develops long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. It's lead candidate, a twice-yearly anti-TSLP agent dubbed WIN378 is undergoing clinical trial to treat asthma and chronic obstructive pulmonary disease. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases
3
Country: USA | Funding: $20M
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
Blossom Health is a telehealth platform that specializes in psychiatry, aiming to provide access to mental health services.
4
Country: USA | Funding: $200M
eMed focuses on employer-sponsored preemptive health management, providing personalized solutions for workforce health.
eMed focuses on employer-sponsored preemptive health management, providing personalized solutions for workforce health.
5
Country: USA | Funding: $25M
Jimini Health develops AI-assisted solutions for behavioral health care, focusing on continuous patient support between clinical sessions.
Jimini Health develops AI-assisted solutions for behavioral health care, focusing on continuous patient support between clinical sessions.
6
Country: USA | Funding: $6.4M
Acurion develops AI-powered oncology precision medicine platform OncoGaze that analyzes genomic biomarkers from routine clinical slides to help clinicians select personalized therapies. The company says OncoGaze can detect genomic biomarkers from routine clinical slides for every cancer, allowing for real-time therapy selection.
Acurion develops AI-powered oncology precision medicine platform OncoGaze that analyzes genomic biomarkers from routine clinical slides to help clinicians select personalized therapies. The company says OncoGaze can detect genomic biomarkers from routine clinical slides for every cancer, allowing for real-time therapy selection.
7
Country: China | Funding: $418.5M
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. The company’s pipeline is headed up by Ori-C101, a GPC3-targeted autologous CAR-T therapy against hepatocellular carcinoma (HCC). The biotech is now gearing up for further studies with the ultimate aim of making Ori-C101 the first globally-approved CAR-T for HCC.
8
Country: USA | Funding: $358M
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. The lead candidate in this pipeline, dubbed TER-2013 - AKT1-selective inhibitor, is already in the clinic as a potential treatment for solid tumors with PIK3CA, AKT or PTEN mutations.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. The lead candidate in this pipeline, dubbed TER-2013 - AKT1-selective inhibitor, is already in the clinic as a potential treatment for solid tumors with PIK3CA, AKT or PTEN mutations.
9
Country: UK | Funding: $125.6M
Storm Therapeutics develops small-molecule therapies that target RNA-modifying enzymes to treat cancer and other diseases. The company conducts a trial of its RNA-modifying enzyme inhibitor against sarcoma.
Storm Therapeutics develops small-molecule therapies that target RNA-modifying enzymes to treat cancer and other diseases. The company conducts a trial of its RNA-modifying enzyme inhibitor against sarcoma.
10
Country: USA | Funding: $106M
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
Tortugas Neuroscience is developing a pipeline of TRTL-107, a D2/D3 partial agonist and 5-HT2A antagonist licensed from China’s Hansoh, and is being evaluated for schizophrenia. The other drug licensed from Hansoh is a GABA receptor-positive allosteric modulator aimed at treating tinnitus.
